Eli Lilly expects to submit a market application for orforglipron for weight management to global regulators by the end of the year.

Jin10 Data reported on April 18 that Eli Lilly announced positive top-line results from the Phase 3 clinical trial ACHIEVE-1, which evaluated the safety and efficacy of orforglipron compared to placebo in patients with type 2 diabetes whose blood sugar control remained inadequate despite dietary control and exercise. Eli Lilly stated that Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to successfully complete a Phase 3 trial without restrictions on diet or fluid intake. Eli Lilly expects to submit a marketing application for orforglipron for weight management to global regulatory agencies by the end of this year, and anticipates submitting its application for the treatment of type 2 diabetes in 2026.